Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of thymalfasin plus interleukin-2 for lymphopenia in hematologic malignancies
ChiCTR2400090033Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2024
- Modality
- Small Molecules, Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thymosin alpha 1 and ibuprofen in lymphocytopenia (3 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete remission rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
thymosin alpha 1ibuprofen
03
Conditions
lymphocytopenia
Beyond the preview
Go deeper on ChiCTR2400090033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090033.